Regional Analysis

Global Herpes Simplex Virus (HSV) Vaccines Market Regional Analysis

Extensive research and development activities in North America are expected to propel herpes simplex virus (HSV) vaccines market growth in the region during the forecast period. Several leading companies are focusing towards research and development of herpes simplex virus (HSV) vaccines for prevention of it. For instance, GEN-003 of Genocea Biosciences, Inc. (based in the U.S.) has shown acceptable safety profile in phase III clinical trials in 2017, so it could be first upcoming vaccine available for HSV in the market boosting global herpes simplex virus (HSV) vaccines market growth.

According to the World Health Organization (WHO) regional infection prevalence estimates for HSV-1 among people range aged 0-49 years are 49% women and 39% men in U.S., 87% women and 87% men in Africa, 69% women and 61% men in Europe, and 74% women and 73% men in western pacific are found, while for HSV-2 are found to be highest in Africa (31.5%) than compared to the U.S. (14.4%). According to the same source, in many emerging economies, herpes simplex virus type-2 (HSV-2) infection is replacing chancroid and syphilis infections as a risk factor in development of genital ulcer diseases.